Abivax

Abivax is a clinical-stage biotechnology company founded in 2013 and headquartered in Paris, France, with a presence in the United States. It develops therapeutics that harness the body's natural regulatory mechanisms to stabilise the immune response in people with chronic inflammatory diseases. Its work spans microRNA biology, immunology, small molecule therapeutics and medicinal chemistry, with activities in both France and the United States.

The company's lead drug candidate is obefazimod, an investigational, once-daily oral small molecule designed to enhance microRNA-124 (miR-124) expression in immune cells. It is being developed initially in ulcerative colitis, with research also under way in Crohn's disease and other inflammatory indications. More than 1,000 subjects have been treated with obefazimod to date.

Beyond obefazimod, Abivax is exploring follow-on compounds and the potential of its proprietary chemical library. Its therapeutic areas include gastroenterology and other chronic inflammatory diseases, and its pipeline remains at the clinical development stage.